2023
Association between sociodemographic factors and diagnosis of lethal prostate cancer in early life
Smani S, Novosel M, Sutherland R, Jeong F, Jalfon M, Marks V, Rajwa P, Nolazco J, Washington S, Renzulli J, Sprenkle P, Kim I, Leapman M. Association between sociodemographic factors and diagnosis of lethal prostate cancer in early life. Urologic Oncology Seminars And Original Investigations 2023, 42: 28.e9-28.e20. PMID: 38161105, DOI: 10.1016/j.urolonc.2023.10.005.Peer-Reviewed Original ResearchLethal prostate cancerSociodemographic factorsAdvanced CaPAdvanced diseaseYounger patientsProstate cancerHigher oddsAdvanced stageProstate-specific antigen (PSA) screeningCharacteristics of patientsNational Cancer DatabaseRetrospective cohort studySubset of patientsPatient sociodemographic factorsMultivariable logistic regressionPatients' health insuranceHighest income quartileCohort studyAdvanced cancerAntigen screeningMean ageInsurance statusCancer DatabaseCaP screeningSociodemographic disparitiesAssociation between sociodemographic factors and diagnosis of advanced prostate cancer in early life.
Smani S, Novosel M, Jeong F, Marks V, Sprenkle P, Leapman M. Association between sociodemographic factors and diagnosis of advanced prostate cancer in early life. Journal Of Clinical Oncology 2023, 41: 32-32. DOI: 10.1200/jco.2023.41.6_suppl.32.Peer-Reviewed Original ResearchAdvanced prostate cancerProstate cancerProstate cancer diagnosisSociodemographic factorsAdvanced diseaseYounger patientsNational Cancer DatabaseCancer diagnosisCharacteristics of patientsRetrospective cohort studySubset of patientsLethal prostate cancerMultivariable logistic regressionEarly prostate cancerHighest income quintileCohort studyAdvanced cancerInsurance statusCancer DatabaseSociodemographic disparitiesInclusion criteriaWhite raceGreater oddsPatientsAdvanced stage
2022
End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy
Dzimitrowicz H, Wilson L, Jackson B, Spees L, Baggett C, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Dinan M, Wheeler S. End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy. JCO Oncology Practice 2022, 19: e213-e227. PMID: 36413741, PMCID: PMC9970274, DOI: 10.1200/op.22.00401.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaOral anticancer agentsDays of lifeRenal cell carcinomaEOL careSystemic therapySEER-MedicareHospital deathCell carcinomaLife careIntensive care unit admissionCancer informationAggressive EOL careHigh-quality EOLOral anticancer therapySystemic therapy useCare unit admissionMultivariable logistic regressionQuality of endUnit admissionED visitsOlder patientsYounger patientsHospital admissionTherapy use
2017
Active Surveillance in Younger Men With Prostate Cancer
Leapman MS, Cowan JE, Nguyen HG, Shinohara KK, Perez N, Cooperberg MR, Catalona WJ, Carroll PR. Active Surveillance in Younger Men With Prostate Cancer. Journal Of Clinical Oncology 2017, 35: jco.2016.68.005. PMID: 28346806, PMCID: PMC5466007, DOI: 10.1200/jco.2016.68.0058.Peer-Reviewed Original ResearchConceptsBiopsy-based Gleason scoreActive surveillanceAssociation of ageProstate cancerDefinitive treatmentRadical prostatectomyYounger patientsGleason scoreMultivariable Cox proportional hazards regressionYounger ageLow-risk prostate cancerCox proportional hazards regressionGleason score upgradeInitial active surveillanceRelated end pointsCox regression analysisKaplan-Meier methodYounger patient ageProportional hazards regressionPrimary study objectiveInitial biopsyMedian agePatient ageHazards regressionBiochemical outcomes